Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 1/20 | 0.59 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.51 |
| ▸ | NAAA | Q02083 | 1/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | USP2 | O75604 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657164 | 0.89 | ALOX5 (0.59) | ALOX5HPGDSMN1; SMN2HDAC3NAAA | |
| SCHEMBL15887763 | 0.87 | ALOX5 (0.79) | ALOX5HPGDHDAC3NAAAHSD17B10 | |
| SCHEMBL16771620 | 0.85 | ALOX5 (0.62) | ALOX5HPGDSMN1; SMN2HDAC3NAAA | |
| SCHEMBL13523839 | 0.82 | NAAA (0.73) | ALOX5HPGDHDAC3NAAAHSD17B10 | |
| SCHEMBL12434384 | 0.82 | NAAA (0.73) | ALOX5HPGDHDAC3NAAAHSD17B10 | |
| SCHEMBL18646228 | 0.79 | HPGD (0.55) | ALOX5HPGDSMN1; SMN2NAAAHSD17B10 | |
| SCHEMBL8980587 | 0.79 | ALDH1A1 (0.55) | ALOX5HPGDSMN1; SMN2HSD17B10HTT | |
| SCHEMBL9492896 | 0.78 | HPGD (0.77) | ALOX5HPGDSMN1; SMN2HDAC3NAAA | |
| SCHEMBL10658522 | 0.77 | HPGD (0.69) | HPGDSMN1; SMN2HDAC3NAAAHTT | |
| SCHEMBL13293977 | 0.77 | HPGD (0.69) | HPGDSMN1; SMN2HDAC3NAAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | EMISPHERE TECHNOLOGIES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178006-A1 | METHOD FOR ADMINISTERING GLP-1 MOLECULES | GLP1R, GIPR, GPR119 | ALOX5 2377/4885HPGD 2135/4885SMN1; SMN2 3138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.